Fluidigm (NASDAQ: FLDM) and HTG Molecular Diagnostics (NASDAQ:HTGM) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.
Institutional and Insider Ownership
94.6% of Fluidigm shares are held by institutional investors. Comparatively, 7.9% of HTG Molecular Diagnostics shares are held by institutional investors. 4.7% of Fluidigm shares are held by insiders. Comparatively, 7.6% of HTG Molecular Diagnostics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This table compares Fluidigm and HTG Molecular Diagnostics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|HTG Molecular Diagnostics||-128.46%||N/A||-109.14%|
Earnings and Valuation
This table compares Fluidigm and HTG Molecular Diagnostics’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Fluidigm||$101.94 million||2.31||-$60.53 million||($1.19)||-5.09|
|HTG Molecular Diagnostics||$14.76 million||6.94||-$18.96 million||($1.79)||-2.02|
HTG Molecular Diagnostics has lower revenue, but higher earnings than Fluidigm. Fluidigm is trading at a lower price-to-earnings ratio than HTG Molecular Diagnostics, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Fluidigm has a beta of 2.99, meaning that its stock price is 199% more volatile than the S&P 500. Comparatively, HTG Molecular Diagnostics has a beta of 1.63, meaning that its stock price is 63% more volatile than the S&P 500.
This is a summary of recent ratings and recommmendations for Fluidigm and HTG Molecular Diagnostics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|HTG Molecular Diagnostics||0||0||3||0||3.00|
Fluidigm presently has a consensus target price of $6.10, suggesting a potential upside of 0.66%. HTG Molecular Diagnostics has a consensus target price of $6.67, suggesting a potential upside of 84.67%. Given HTG Molecular Diagnostics’ stronger consensus rating and higher possible upside, analysts clearly believe HTG Molecular Diagnostics is more favorable than Fluidigm.
HTG Molecular Diagnostics beats Fluidigm on 7 of the 13 factors compared between the two stocks.
Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment. Its products include preparatory instruments, preparatory analytical instruments, analytical instruments, integrated fluidic circuits (IFCs), and assays and reagents. Its preparatory instruments include C1 Single-Cell Auto Prep System, Access Array System, Juno System and IFCs, and Callisto System and IFC. Its analytical instruments include Biomark HD System, EP1 System and Helios/CyTOF 2 System. Its assays and reagents include Delta Gene and SNP Type Assays, and Access Array Target-Specific Primers and Targeted Sequencing Prep Primers.
About HTG Molecular Diagnostics
HTG Molecular Diagnostics, Inc. is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development. The Company’s HTG Edge and HTG EdgeSeq platforms automate the molecular profiling of genes and gene activity using its nuclease protection chemistry on a range of biological samples. The Company’s HTG EdgeSeq chemistry, together with its HTG Edge or HTG EdgeSeq instrumentation and software, automates and adapts its nuclease protection chemistry to enable analysis using next generation sequencing (NGS) instrumentation. The HTG EdgeSeq system utilizes substantially the same sample preparation reagents as its original chemistry, but allows for read out on an NGS instrument.
Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.